Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Gastroenterology

FAP Beyond the Colon: Other Signs and Risks

At a Glance

While FAP is known for causing colon polyps, the APC gene mutation affects the whole body. Extracolonic manifestations include harmless markers like eye freckles and bone growths, as well as conditions requiring careful screening like upper GI polyps, thyroid cancer risks, and desmoid tumors.

While Familial Adenomatous Polyposis (FAP) is often defined by what happens in the colon, the APC gene mutation affects cells throughout your entire body. This means that symptoms can appear outside of the digestive tract. These are known as extracolonic manifestations [1][2].

Understanding these “extra” features is important because they require their own monitoring and management plans. Some are harmless markers that help with diagnosis, while others require proactive screening to ensure they are managed early [3][4].

Diagnostic Clues: The Eyes and Bones

Some signs of FAP are completely harmless but act as “red flags” that can lead doctors to the correct diagnosis.

  • CHRPE (Eye Freckles): These are small, dark, flat spots on the retina at the back of the eye, called Congenital Hypertrophy of the Retinal Pigment Epithelium [3][5]. They do not affect your vision, but having multiple lesions in both eyes is highly specific to FAP [6][5].
  • Osteomas and Dental Anomalies: Many patients develop osteomas, which are non-cancerous, hard bony growths often found on the jaw or skull [4][7]. You might also have dental issues like extra teeth, missing teeth, or teeth that fail to emerge (impacted teeth) [4].

Managing Desmoid Tumors

One of the more complex aspects of FAP is the desmoid tumor. These are firm, scar-like growths that develop in about 10% of people with FAP [8].

  • Nature: While they are not cancer (they do not spread to other organs), they can be aggressive because they grow into nearby tissues, such as the abdominal wall or the small intestine [8][9].
  • Management: In the past, doctors often rushed to remove these surgically. However, because surgery can actually trigger more growth and has a high recurrence rate, the modern approach is often active surveillance—a “watch-and-wait” strategy [10][11][12].
  • Treatment: If a desmoid tumor is growing or causing pain, doctors may use medications like tyrosine kinase inhibitors or specialized hormone therapies instead of surgery [13][14].

Other Organs Requiring Surveillance

Because the APC gene mutation is present in all your cells, other organs need regular “check-ups” using a personalized roadmap [2].

The Upper GI Tract

The duodenum (the first part of the small intestine just after the stomach) is a common site for polyps in FAP [2]. Doctors use the Spigelman staging system to grade these polyps and decide how often you need an upper endoscopy (a camera test through the mouth) [15][16].

The Thyroid

There is a specific, rare type of thyroid cancer called cribriform-morular variant papillary thyroid carcinoma (CMV-PTC) associated with FAP [17][18]. It is most common in young women [18]. Because of this, regular thyroid ultrasounds are usually recommended starting in the teens or twenties [19][18].

Rare Risks

  • Hepatoblastoma: A rare liver tumor that typically occurs in children under age 5 with FAP. Early childhood screening with abdominal ultrasounds and an Alpha-fetoprotein (AFP) blood test is often discussed for families with a known history [1].
  • Medulloblastoma: A rare brain tumor associated with the Turcot syndrome variant of FAP [20][21].

Personalized Monitoring

Not everyone with FAP will experience every one of these manifestations. Your risk is often tied to your genotype—the specific location of the mutation on your APC gene [22][23]. For example, mutations in certain regions of the gene are linked more strongly to desmoid tumors, while others are linked to CHRPE [24][23]. Your medical team will use your genetic results to determine which screenings are most critical for you.

Common questions in this guide

What are extracolonic manifestations in FAP?
Extracolonic manifestations are symptoms and growths that occur outside of the colon as a result of the APC gene mutation. These can include harmless markers like eye freckles or bony growths, as well as conditions requiring active management like desmoid tumors and thyroid issues.
What is a desmoid tumor in FAP?
A desmoid tumor is a firm, non-cancerous, scar-like growth that develops in some people with FAP. While they do not spread to other organs, they can grow aggressively into nearby tissues and are typically managed with a watch-and-wait approach or specialized medications rather than surgery.
Does FAP increase my risk for other types of cancer?
Yes, FAP can increase the risk of certain cancers outside the colon. The most common is a specific type of thyroid cancer, which is why regular thyroid ultrasounds are recommended. In rare cases, it can also be associated with childhood liver tumors or brain tumors.
What are CHRPE eye freckles?
CHRPE stands for Congenital Hypertrophy of the Retinal Pigment Epithelium, which are small, dark, flat spots on the back of the eye. They do not affect your vision, but having multiple eye freckles is a strong diagnostic clue for FAP.
Why do I need upper endoscopies if I have FAP?
The APC gene mutation also causes polyps to form in the upper gastrointestinal tract, specifically the duodenum. Doctors use upper endoscopies and the Spigelman staging system to monitor these polyps and manage them before they can become problematic.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific APC gene mutation, which extracolonic manifestations (like desmoids or thyroid issues) should we be most watchful for?
  2. 2.When should I have my first baseline thyroid ultrasound, and how often should it be repeated?
  3. 3.I've heard about the Spigelman staging system for the upper GI tract; what is my current stage and how does it affect my surveillance?
  4. 4.If I develop a desmoid tumor, does your team include a specialist who uses modern 'watch-and-wait' or systemic therapy approaches instead of immediate surgery?
  5. 5.Can you refer me to an ophthalmologist who is familiar with CHRPE in FAP patients?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan.

    Mori Y, Amano K, Chikatani K, et al.

    International journal of clinical oncology 2022; (27(6)):1034-1042 doi:10.1007/s10147-022-02146-4.

    PMID: 35274183
  2. 2

    Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.

    Zaffaroni G, Mannucci A, Koskenvuo L, et al.

    The British journal of surgery 2024; (111(5)) doi:10.1093/bjs/znae070.

    PMID: 38722804
  3. 3

    Use of congenital hypertrophy of the retinal pigment epithelium as a clinical sign of familial adenomatous polyposis.

    Carvalho AA, Crespo TS, Násser LS, et al.

    Arquivos brasileiros de oftalmologia 2024; (88(3)) doi:10.5935/0004-2749.2023-0115.

    PMID: 39607153
  4. 4

    Study of diagnostic value of congenital hypertrophy of retinal pigment epithelium in Chinese familial adenomatous polyposis patients.

    Cai S, Yu Y, Xie X, et al.

    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2022; (31(5)):422-429 doi:10.1097/CEJ.0000000000000725.

    PMID: 35191403
  5. 5

    Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE) as a Screening Marker for Familial Adenomatous Polyposis (FAP): Systematic Literature Review and Screening Recommendations.

    Bonnet LA, Conway RM, Lim LA

    Clinical ophthalmology (Auckland, N.Z.) 2022; (16()):765-774 doi:10.2147/OPTH.S354761.

    PMID: 35321042
  6. 6

    Congenital Hypertrophy of Retinal Pigment Epithelium for Diagnosis of Familial Adenomatous Polyposis - the First FAP registry in Iran

    Mirinezhad SK, Mousavi F, Baghri M, et al.

    Asian Pacific journal of cancer prevention : APJCP 2018; (19(1)):167-169 doi:10.22034/APJCP.2018.19.1.167.

    PMID: 29373909
  7. 7

    Rare Germline Variants in the Adenomatous Polyposis Coli Gene Associated with Dental and Osseous Anomalies.

    Büki G, Antal G, Bene J

    International journal of molecular sciences 2024; (25(15)) doi:10.3390/ijms25158189.

    PMID: 39125758
  8. 8

    Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis.

    Koskenvuo L, Peltomäki P, Renkonen-Sinisalo L, et al.

    Journal of surgical oncology 2016; (113(2)):209-12 doi:10.1002/jso.24117.

    PMID: 26663236
  9. 9

    Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.

    Takahashi T, Prensner JR, Robson CD, et al.

    Pediatric blood & cancer 2020; (67(10)):e28636 doi:10.1002/pbc.28636.

    PMID: 32762028
  10. 10

    Active surveillance and emerging medical treatment options for desmoid: when and for whom?

    Bonvalot S, Miah A, Kasper B

    Current opinion in oncology 2024; (36(4)):263-268 doi:10.1097/CCO.0000000000001049.

    PMID: 38726846
  11. 11

    Desmoid-type fibromatosis: toward a holistic management.

    Penel N, Kasper B, van Der Graaf WTA

    Current opinion in oncology 2021; (33(4)):309-314 doi:10.1097/CCO.0000000000000743.

    PMID: 33973549
  12. 12

    Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.

    Quast DR, Schneider R, Burdzik E, et al.

    Familial cancer 2016; (15(1)):31-40 doi:10.1007/s10689-015-9830-z.

    PMID: 26275868
  13. 13

    Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.

    Gounder M, Ratan R, Alcindor T, et al.

    The New England journal of medicine 2023; (388(10)):898-912 doi:10.1056/NEJMoa2210140.

    PMID: 36884323
  14. 14

    Sorafenib for Advanced and Refractory Desmoid Tumors.

    Gounder MM, Mahoney MR, Van Tine BA, et al.

    The New England journal of medicine 2018; (379(25)):2417-2428 doi:10.1056/NEJMoa1805052.

    PMID: 30575484
  15. 15

    Predicting Duodenal Cancer Risk in Patients with Familial Adenomatous Polyposis Using Machine Learning Model.

    Akbulut S, Küçükakçalı Z, Çolak C

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2023; (34(10)):1025-1034 doi:10.5152/tjg.2023.22346.

    PMID: 37565794
  16. 16

    Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer.

    Tanakaya K, Yamaguchi T, Hirata K, et al.

    International journal of clinical oncology 2026; (31(1)):1-66 doi:10.1007/s10147-025-02892-1.

    PMID: 41214301
  17. 17

    Clinicopathological and molecular mechanisms of cribriform morular thyroid carcinoma: a case report and a literature review.

    Zhang X, Lv Y, Yan W, et al.

    Annals of medicine and surgery (2012) 2025; (87(12)):8944-8948 doi:10.1097/MS9.0000000000004082.

    PMID: 41377377
  18. 18

    Cribriform-Morular Variant of Papillary Thyroid Carcinoma: Clinical and Pathological Features of 30 Cases.

    Akaishi J, Kondo T, Sugino K, et al.

    World journal of surgery 2018; (42(11)):3616-3623 doi:10.1007/s00268-018-4644-4.

    PMID: 29696324
  19. 19

    Age- and Gender-Specific Risk of Thyroid Cancer in Patients With Familial Adenomatous Polyposis.

    Uchino S, Ishikawa H, Miyauchi A, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4611-4617 doi:10.1210/jc.2016-2043.

    PMID: 27623068
  20. 20

    [Meduloblastoma and recurrent meningioma in association with colonic polyposis: an unusual presentation of Turcot syndrome].

    Barreda Costa C, Chu Revollar L, Herrera Alzamora A

    Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 2019; (39(3)):280-283.

    PMID: 31688854
  21. 21

    Systemic considerations with pigmented fundus lesions and retinal pigment epithelium hamartomas in Turcot syndrome.

    Mokhashi N, Cai LZ, Shields CL, et al.

    Current opinion in ophthalmology 2021; (32(6)):567-573 doi:10.1097/ICU.0000000000000798.

    PMID: 34456292
  22. 22

    Aggressive mutation in a familial adenomatous polyposis syndrome family: when phenotype guides clinical surveillance.

    Neffa F, Garcia L, Della Valle A, et al.

    Journal of gastrointestinal oncology 2018; (9(3)):553-559 doi:10.21037/jgo.2017.10.06.

    PMID: 29998021
  23. 23

    In patients with a positive family history of familial adenomatous polyposis can the condition be diagnosed from the presence of congenital hypertrophy of the retinal pigment epithelium detected via an eye examination: A systematic review.

    Rehan S, Aye K

    Clinical & experimental ophthalmology 2020; (48(1)):98-116 doi:10.1111/ceo.13643.

    PMID: 31525261
  24. 24

    Desmoid tumors complicating Familial Adenomatous Polyposis: a meta-analysis mutation spectrum of affected individuals.

    Slowik V, Attard T, Dai H, et al.

    BMC gastroenterology 2015; (15()):84 doi:10.1186/s12876-015-0306-2.

    PMID: 26179480

This page provides educational information about extracolonic manifestations of FAP. Always consult your genetics team and specialists to determine the right screening and surveillance plan for your specific APC mutation.

Get notified when new evidence is published on Familial Adenomatous Polyposis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.